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There is some evidence that insulin-like growth factor 2 (IGF-2) may intervene in the control of T cell differentiation. To further
study the immunoregulatory function of this growth factor, we analyzed the immune system of Igf2/ mice. Phenotypically, some
immunological parameters such as lymphoid organ morphology and cellularity were unaltered in Igf2/ mice, but an increase
of CD8 cells and a decrease of B220 cells were observed in spleen. In vitro, the development of bone marrow-derived dendritic
cells was affected by the absence of Igf2 expression. After maturation, a higher percentage of immature dendritic cells was
observed in Igf2/ population, together with a secondary decrease in allogenic T cell proliferation. Activation of T cells was also
affected by the lack of expression of this growth factor. The profile of B cell response in mutant mice immunized with IGF-2
evidenced a T-dependent profile of anti-IGF-2 Abs that was absent in Igf2/ mice. The influence of IGF-2 upon tolerance to
insulin was also assessed in this model, and this showed that IGF-2 also intervenes in tolerance to insulin. The presence of a
T-dependent response in Igf2-deficient mice should allow cloning of specific “forbidden” T CD4 lymphocytes directed against
IGF-2, as well as further investigation of their possible pathogenic properties against insulin family. The Journal of Immunology,
2006, 176: 4651–4657.
I nsulin-like growth factors 1 and 2 (IGF-1/2)3 are members ofthe insulin hormone family that exert a prominent role in fetaland postnatal development (1, 2). Null mutant mice for Igf1
show a marked growth deficiency with 60% of normal body
weight, a variable neonatal lethality frequency depending on ge-
netic background, and they are infertile (3). The absence of Igf2
induces similar growth failure, but Igf2/ mice are viable and
fertile (4, 5).
With regard to the implication of IGF in immune physiology
and development, most of the studies have focused on the growth
hormone/IGF-1 axis and type 1 IGF receptor (IGF-1R), a trans-
membrane tyrosine kinase homologous to the insulin receptor that
mediates most of the biological effects of IGF-1 and IGF-2 (6, 7).
Normal development and ex vivo activation of T and B cells are
observed in chimeric Rag2-deficient C57BL/6 mice reconstituted
with fetal liver cells from Igf1r/ mice. However, this model
revealed an unexpected decrease of the T-independent B cell re-
sponse which is important in bacterial defense mechanisms (8).
So far, very few studies have investigated the function of IGF-2
in immune development and physiology. This growth factor is the
dominant peptide of the insulin family expressed in the thymus
epithelium of different species (9, 10). Thymic IGF-2 influences
thymic development and T cell differentiation as evidenced by
analysis of IGF-2 transgenic dwarf mice, which develop a thymic
hyperplasia (11) with an increased number of thymocytes (and
CD4 T lymphocytes in particular) (12, 13). This increase of T
cells is also observed in the spleen compartment of IGF-2 trans-
genic mice, but there is no significant effect on B cell development.
In vitro, T cell differentiation and proliferation are also impaired in
fetal thymic organ culture treated with anti-IGF-2, anti-IGF-1R, or
anti-IGF-2R. In these experimental conditions, T cell differentia-
tion is inhibited at early CD4 CD8 stage, whereas anti-IGF-2
induces an increase in thymic CD8 T cells suggesting a role for
IGF-2 in T cell final commitment to CD4 or CD8 lineage (14).
Finally, a role of thymic IGF-2 in central immune self-tolerance of
the insulin family has been suggested by the observation of a de-
fect of Igf2 transcription in the thymus of Bio-Breeding (BB) rats,
an animal model of type 1 diabetes (15).
In this study, we further investigate the role played by IGF-2 in
the immune function through the use of Igf2-deficient mice. Al-
though Igf2 deficiency does not interfere with the development of
major lymphoid structures, bone marrow (BM)-derived dendritic
cells (DC) from Igf2-deficient mice show a defect of maturation as
evidenced by a higher persistence of immature DC (iDC) com-
pared with wild-type (wt) mice. This is associated with a decrease
of ability of Igf2/ DC to activate allogenic T lymphocytes in
MLR. T cell proliferation assessed by MLR is also severely im-
paired. The profile of the immune responses against IGF-2 and
insulin in mutant mice was also evaluated and shows that tolerance
to IGF-2 depends on Igf2 expression, but that IGF-2 also contrib-
utes to tolerance to insulin.
Materials and Methods
Animals
Igf2/ mice were provided by Dr. A. Efstratiadis and were bred at the
Animal Department of Liege University under conventional conditions
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with free access to food and water. DNA for typing was prepared from tail
biopsies. BALB/c mice were also bred under the same conditions. Male
and female mice were 5–8 wk old at the time of experiments, which were
performed in agreement with the local ethic committee.
Phenotype of mice
Igf2/ and wt mice were weighed and were sacrificed by cervical dislo-
cation. The thymus and the spleen were removed and weighed. The number
of living cells was estimated by trypan blue dye exclusion.
Generation of BM-derived DC
BM-derived DC were isolated and differentiated according to the method
developed by Lutz et al. (16). Briefly, Igf2/ and wt mice were sacrificed
by cervical dislocation and femur/tibiae were removed and freed of mus-
cles and tendons. Both ends were cut with scissors and BM cells were
flushed with DPBS without Ca2 and Mg2 (Cambrex) using a syringe
with a needle 0.45 mm in diameter. Cell suspension was filtered through a
70-m cell strainer (BD Biosciences) to remove remaining bone frag-
ments. At day 0, the cells were seeded at 2  105 cells/ml in 100-mm petri
dishes (Falcon no. 1029; VWR International) and 10 ml per dish. The
medium used during differentiation (10 days) to obtain iDC was RPMI
1640 supplemented with penicillin (100 U/ml), streptomycin (100 g/ml),
L-glutamine (2 mM) (Cambrex), 2-ME (50 M), 10% heat-inactivated FCS
(Invitrogen Life Technologies) and recombinant murine (rm) GM-CSF (20
ng/ml, personal production). The vector pcDNA GM-CSF was a gift from
J.-C. Renauld (Universite´ Catholique de Louvain, Brussels, Belgium) and
rmGM-CSF was produced by COS-7 transfection using FuGENE 6 trans-
fection reagent (Roche) according to the manufacturer’s instructions. At
day 3, an additional 10 ml of complete medium containing rmGM-CSF (20
ng/ml) per dish were added, and at day 6 and 8, 10 ml were collected,
centrifuged at 200  g for 7 min. The cell pellet was resuspended in fresh
complete medium with rmGM-CSF (20 ng/ml) and was plated again. At
day 10, the maturation to mDC was performed in 100 mm tissue culture
petri dishes (Falcon no. 3003; VWR International) with the same medium
containing rmGM-CSF (10 ng/ml) and LPS (2.5 g/ml, Escherichia coli
O26:B6; Sigma-Aldrich) for 24 or 48 h. For this step, the cells were seeded
at 1.5  105 cells/ml and 10 ml per plate.
RNA isolation
Total RNA was extracted from BM cells, iDC, mDC, and 16-day-old fetal
brains using RNeasy Mini kit (catalog no. 74104; Qiagen) according to the
manufacturer’s instructions. Pancreas and liver total RNA was isolated
using Tripure isolation reagent (Roche). DNA contamination was removed
by treatment of samples with RNase-free DNase (Roche). RNA was dosed
with the RiboGreen RNA quantitation kit (Molecular Probes).
Actin, Insulin 1 (Ins1), Insulin 2 (Ins2), Igf1, Igf2, Igf1r, Igf2r
RT-PCR and sequencing
Total RNA (250–500 ng) was reverse transcribed in a total of 20 l by the
1st Strand cDNA synthesis kit for RT-PCR (AMV; Roche) using oli-
go(dT)primer. Reverse-transcription products (1:20) were used directly for
PCR using FastStart TaqDNA polymerase (Roche) according to the man-
ufacturer’s instructions in a UNO II rapid thermocycler (Biometra). After
a denaturation step at 94°C for 5 min, the samples were submitted to 35
cycles comprising 94°C for 45 s, variable temperature depending on prim-
ers for 45 s and 72°C for 45 s. To finish, an additional elongation step was
performed at 72°C for 7 min. PCR products were analyzed in 2% agarose
ethidium bromide-staining gels. The sequence of primers and the respec-
tive temperature are presented in Table I. The PCR products were se-
quenced (Genome Express) using their respective primers.
Flow cytometry
Immature DC, mDC, fresh thymocytes, BM cells, and splenic cells (5 
105-106) were centrifuged at 200  g for 5 min and prepared in 100 l of
DPBS (Cambrex) for labeling. Cell preparations were stained for 20 min at
4°C and washed one time in DPBS.
Flow cytometric analyses were performed with FACStarPlus (BD Bio-
sciences). Abs (BD Biosciences) were CD86-PE clone GL1 (rat IgG2a),
CD80-PE clone 16-10A1 (Armenian hamster IgG), Gr-1/Ly6G-PE clone
RB6-8C5 (rat IgG2b), I-A/I-E-PE clone M5/114.15.2 (rat IgG2b), CD11c-
FITC clone HL3 (Armenian hamster IgG), CD8-FITC clone 53-6.7 (rat
IgG2a), CD45R/B220-PE clone RA3-6B2 (rat IgG2a), and CD4-PE clone
RH4-5 (rat IgG2a). The data analysis was performed using CellQuest soft-
ware (BD Biosciences).
The MLR
The capacity of DC from wt and Igf2/ mice on T cell activation was
evaluated in a primary allogenic MLR. DC were harvested after 24 h of
maturation with LPS and used as T cell stimulators after 3000 rad of gam-
ma-irradiation. BALB/c spleen cell responders were prepared by mechan-
ical disruption, erythrocyte lysis (Hybrid-Max; Sigma-Aldrich), and
filtration through a 70-m cell strainer (BD Biosciences). The MLR was
performed with 106 responders  105 irradiated stimulators/ml in RPMI
1640 supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 2
mM L-glutamine, 1 mM sodium pyruvate, 1% MEM nonessential acid, 10
mM HEPES (Cambrex), 50 M 2-ME (Invitrogen Life Technologies), and
10% heat-inactivated FCS (Invitrogen Life Technologies). The cells were
incubated in 5% CO2 at 37°C.
Igf2/ and wt T cell proliferation was also assessed by MLR. BALB/c
BM-derived DC were used as stimulators after 3000 rad of gamma-irra-
diation. Igf2/ and wt T cell responders were prepared by mechanical
disruption, erythrocyte lysis (Hybrid-Max; Sigma-Aldrich), and filtration
through 70 m cell strainer (BD Biosciences). The MLR was performed
with 106 responders 105 gamma-irradiated stimulators/ml in RPMI 1640
supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM
L-glutamine, 1 mM sodium pyruvate, 1% MEM nonessential acid, 10 mM
HEPES (Cambrex), 50 M 2-ME (Invitrogen Life Technologies), and 10%
heat-inactivated FCS (Invitrogen Life Technologies). The cells were incu-
bated in 5% CO2 at 37°C.
After 0, 48, and 96 h, 800 l of culture were collected and distributed
in triplicate on 96-well flat-bottom (200 l/well). Then, 0.5 Ci of [3H]thy-
midine (Amersham Biosciences) was added to each well for an additional
18 h of culture. Cellular DNA was harvested using a Titertek cell harvester
(Flow Laboratories), and scintillation counting was performed in a Beck-
man liquid scintillation counter (BD Biosciences). wst-1 tests were per-
formed with 10 l of wst-1 Cell Proliferation Reagent (Roche) for an
additional 4 h of culture. The absorbance was measured at 450–620 nm.
Table I. Synthetic primers selected for RT-PCR and sequencing





Ins1 Sense AGACCATCAGCAAGCAGGTC 65°C 324 17
Antisense CTGGTGCAGCACTGATCCAC
Ins2 Sense GTGGAGGACCCACAAGTGG 65°C 198 17
Antisense ATTCATTGCAGAGGGGTAGGCT
Igf1 Sense GCTGAGCTGGTGGAATGCTCTTCAGTTC 55°C 215 18
Antisense CTTCTGAGTCTTGGGCATGTCAGTGTG
Igf2 Sense GAGCTTGTTGACACGCTTCAGTTTGTC 55°C 356 18
Antisense ACGTTTGGCCTCTCTGAACTCTTTGAG
Igf1r Sense GACATCCGCAACGACTATCAG 50°C 395 19
Antisense GTAGTTATTGGACACCGCATC
Igf2r Sense CTGGAGGTGATGAGTGTAGCTTGGC 55°C 235 20
Antisense GAGTGACGAGCCAACACAGACAGGTC
Actin Sense TAAAGACCTCTATGCCAACACAGT 54°C 250 21
Antisense CACGATGGAGGGGCCGGACTCATC
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Mice immunization
Igf2/ and wt mice were injected i.p. with 5 g of rmIGF-2 (R&D Sys-
tems) or with 5 g of human insulin (Roche) to study the humoral response
and with 50 g of murine IGF-2-derived B11-25 (NEOSYSTEM) to an-
alyze the cellular response. CFA (Sigma-Aldrich) (v/v) is used for the first
injection and IFA (Sigma-Aldrich) (v/v) for the other injections. For hu-
moral response, three injections separated by 20 days were performed.
Blood test was performed 15 days after each injection in agreement with
the Liege University ethic committee. For cellular response, two injections
separated by 15 days were performed.
Dosage of anti-IGF-2 and anti-insulin Abs
Abs against IGF-2 and insulin were detected and quantified using a specific
ELISA procedure. Microplates (Nunc Maxisorp 468667; VWR Interna-
tional) were incubated overnight at 4°C with 2 g/ml rmIGF-2 (R&D
Systems) or 5 g/ml human insulin (Roche) in 100 l of 0.1 M NaHCO3
(pH 8.4). From this step, the procedure was identical between the two kinds
of ELISA. SL buffer (0.01 M phosphate buffer, pH 7.4) was used as the
basic buffer, and all reactions were incubated at 37°C under agitation. To
block nonspecific binding, 200 l of SL buffer containing 1% of BSA
(Sigma-Aldrich) was added per well for 2 h. Four washes with 0.01 M
phosphate buffer with 0.5‰ of Tween 20 (washing buffer) were performed,
and the sera were diluted in SL buffer containing 0.5% BSA and 0.1%
Tween 20 (VWR International) and incubated to 100 l/well for 2 h. After
four washes, the samples were incubated with peroxidase-labeled anti-
mouse Abs diluted in the same buffer at a different concentration: 1/4000
for anti-IgG (Prosan), 1/2000 for anti-IgG1, 1/2000 for anti-IgG2a, 1/2000
for anti-IgG2b, 1/2000 for anti-IgG3, and 1/3000 for anti-IgM (Serotec).
The incubation was performed in 100 l for 1 h. The microplates were
washed 4 times and 200 l/well of substrate buffer (TMB; Biosource Eu-
rope) were added for 20 min at room temperature under agitation. The
reaction was stopped with 50 l of 0.4 N HCl, and the absorbance was
measured at 450–620 nm with a spectrophotometer.
Specific T cell culture
After immunization with murine IGF-2-derived B11-25, spleen cells were
prepared by mechanical disruption, erythrocyte lysis (Hybrid-Max; Sigma-
Aldrich), and filtration through a 70-m cell strainer (BD Biosciences).
The culture was performed with 3  106 spleen cells without or with
murine IGF-2-derived B11-25 (20 g/ml) in Ex vivo-15 medium (Cam-
brex) supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 2
mM L-glutamine, 1 mM sodium pyruvate, 1% MEM nonessential acid, 10
Table II. Comparison of surface phenotype on Igf2/ and Igf2/
mDC (n  5 of each genotype)
Igf2/ Igf2/
A
CD11c Ly6G 76.79  9.191 67.76 6.224*
CD11c Ly6G 9.10  3.660 19.18 6.116*
B
CD80low/int 21.45  12.85 37.22 13.94*
CD80high 78.82  13.10 63.17 13.97*
CD86low/int 19.60  12.01 39.21 16.62*
CD86high 80.60  12.22 61.19 16.58*
MHC-IIlow/int 21.34  17.56 38.94 15.45*
MHC-IIhigh 78.68  17.53 61.16 15.34*
*, p  0.05; mean (%)  SD.
FIGURE 1. Analysis of Igf2/
and Igf2/ phenotype. A, Thymic and
splenic weights of Igf2/ and Igf2/
mice (n  4 of each genotype). Tissue
weights were calculated in percentage
of total body weight. B, Cellularity of
Igf2/ (filled histogram) and Igf2/
(hatched histogram) in BM, thymus,
and spleen. The number of Igf2/
cells was expressed in percentage of
Igf2/ cells (100%) (n  8 of each
genotype). C, Lymphoid cell sub-
classes (%) in spleen of the two kinds
of mice. These subclasses were ana-
lyzed by flux cytometry (n 8 of each
genotype). Mean  SD; *,
p  0.05.
FIGURE 2. Expression of insulin family genes and their receptors in
BM (lane 1), iDC (lane 2), and mDC (lane 3) by RT-PCR. H2O served as
negative control (lane ). Liver and pancreas served as positive control
(lane ) for Igf1 and Igf2, and Ins1 and Ins2, respectively. Fetal brain was
the positive control (lane ) for Igf1r and Igf2r. M represented the m.w.
marker (lane M). One experiment representative of three individual exper-
iments is shown.
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mM HEPES (Cambrex), and 50 M 2-ME (Invitrogen Life Technologies).
The cells were incubated in 5% CO2 at 37°C.
IL-2 production
After 48, 72, and 96 h of MLR or after 24 and 48 h of specific T cell
culture, 800 l were removed of each condition and IL-2 production re-
leased by Igf2/ and wt T cells in MLR was assessed by specific ELISA
(Biosource Europe).
Statistical analyses
One way ANOVA was used for MLR experiments (Newman-Keuls post-
test) and t test was used to compare Igf2/ and wt mice in cytometric
experiments, IL-2 production, and Ab production after immunization. The
level of significance was p  0.05.
Results
Normal phenotype of lymphoid organs in Igf2-deficient mice
Igf2/ mice presented a significant reduced body weight (61.6%
of normal body weight) when compared with wt mice. Thymus
and spleen from mutant mice were not significantly affected by the
deletion of this gene because they presented a similar size and
morphology compared with wt organs (Fig. 1A). The cellularity of
different lymphoid organs such as thymus, spleen, and BM, was
also analyzed and did not show any significant difference between
wt and Igf2/ mice. The number of Igf2/ cells in the three
studied organs was reduced in the same proportion than the size
reduction (60%) (Fig. 1B). In vivo analyses of lymphoid compart-
ment (T and B lymphocytes) showed no significant difference in
thymocyte subpopulations (data not shown). In spleen, T cell anal-
ysis revealed no difference for CD4CD8 cells, CD4CD8
cells and CD4CD8 cells but the CD4CD8 population was
significantly higher in mutant mice compared with wt mice.
Igf2/ mice also presented a significant decrease of B cell pop-
ulation (B220 cells) (Fig. 1C).
Influence of IGF-2 on DC differentiation and maturation
Insulin-related genes and their receptors expressed by BM, iDC,
and mDC. RNA expression of Igf1, Igf2, Ins1, Ins2, and their
receptors Igf1r and Igf2r was assessed by RT-PCR with specific
primers. The positive controls were liver for Igf1 and Igf2, fetal
brain for Igf1r and Igf2r, and pancreas for Ins1 and Ins2. Negative
control was H2O. Igf1, Igf2, Igf1r, and Igf2r transcripts (215, 356,
395, and 235 bp, respectively) were detected in wt BM cells, wt
iDC, and wt mDC extracts but, on the other hand, neither Ins1, nor
Ins2 transcripts (324 and 198 bp, respectively) were found in wt
DC samples contrary to positive controls (Fig. 2). The semiquan-
titative PCR pattern suggested that Igf2 expression is up-regulated
between iDC and mDC. Sequencing of Igf1, Igf2, Ins1, Ins2, Igf1r,
and Igf2r PCR products confirmed the specificity and the selec-
tivity of different primers. Each product presented 97–100% ho-
mology compared with their respective GenBank sequence. All
genes detected in wt samples were found in Igf2/ BM cells,
Igf2/ iDC and Igf2/ mDC except Igf2 for which the expres-
sion was severely decreased.
Surface phenotype of iDC and mDC is affected by deficiency of
Igf2 expression. DC population was determined by analysis of
CD11c expression in flow cytometry. From day 0 to day 11, wt
FIGURE 3. Comparison of surface expression of MHC-II, CD80, and
CD86 by iDC (A) and mDC (B) from wt (filled histograms) and Igf2/
mice (open histograms). Flow cytometric analysis of gated CD11c cells
represent the three markers implicated in Ag presentation and T cell acti-
vation. After 10 days with rmGM-CSF, BM cells were differentiated to
iDC. Maturation was performed with rmGM-CSF and LPS for 24 h. One
experiment representative of five individual experiments is shown.
FIGURE 4. Implication of IGF-2 in DC activation capacity and in T cell proliferation. A, Igf2/ and Igf2/ DC capacity to stimulate BALB/c spleen
cells in MLR. B, wt and Igf2/ spleen cell proliferation in MLR with BALB/c DC stimulators. Proliferations was assessed by [3H]thymidine uptake and
measured after 48 and 96 h. Data are expressed as growth percentage vs time (h). Mean SD; *, p 0.01, one experiment representative of three individual
experiments is shown, each performed in triplicate (n  3 of each genotype). C, IL-2 production of Igf2/ and Igf2/ spleen cells after 48 h of culture
(n  8 of each kind of mice).
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CD11c cells increased in the same way than Igf2/ CD11c
cells to reach 84.75  10.75% and 86.94  10.46%, respectively,
at mature stage. The percentage of CD11c cell population from
Igf2-deficient mice was identical than the CD11c population
from wt mice. These CD11c cells showed no CD8 expression
during differentiation and maturation. Among mature CD11c
cells, two populations were analyzed: CD11cLy6G cells and
CD11cLy6G cells. The distribution of these classes was mod-
ulated according to the origin of cells: the wt CD11cLy6G pop-
ulation was significantly higher than Igf2/ CD11cLy6G pop-
ulation, and this was the opposite for CD11cLy6G cells (Table
II, part A). This difference was not observed at day 10 but only
after maturation. CD11cLy6G population was also analyzed
and showed no difference between wt and mutant mice after dif-
ferentiation and maturation (data not shown). Expression of dif-
ferent molecules involved in T cell activation such as class II MHC
(MHC-II), CD80, and CD86 was assessed by flow cytometry on
CD11c cells. After differentiation (Fig. 3A), wt iDC expressed a
low or intermediate level of the three markers, with no significant
difference with Igf2/ iDC. In wt mice, LPS treatment promoted
overexpression of these molecules during DC maturation (Fig.
3B). The persistence of iDC population with a lower expression of
MHC-II, CD80, and CD86 was higher in Igf2/ culture com-
pared with wt culture (Table II, B). This immature population in
Igf2/ culture was observed after 24 and 48 h of maturation.
Higher iDC population influences T cell activation. The influence
of a higher iDC population in Igf2/ mice on T cell activation
was studied using [3H]thymidine incorporation assays (Fig. 4A).
After 48 h of MLR, a significant decrease in T cell proliferation
with Igf2/ DC was observed when compared with wt DC. The
decreased proliferation with Igf2/ DC was time persistent and
still observed after 96 h of MLR.
IGF-2 influence on T cell proliferation and activation
The absence of Igf2 expression in T lymphocytes caused a signif-
icant decrease of proliferation of spleen cells as shown by [3H]thy-
midine incorporation assays (Fig. 4B). A similar decrease was ob-
served with wst-1 tests but did not reach the level of significance
(data not shown). This reduction of proliferation was persistent
until 120 h of MLR. However, no significant difference in IL-2
production was observed between wt and Igf2/ culture along the
time of culture (Fig. 4C).
Characterization of anti-IGF-2-specific immune responses
Igf2/ and wt mice were immunized with IGF-2 to characterize
anti-IGF-2-specific immune responses. The analysis of humoral
response (Fig. 5A) showed that immunization of Igf2-deficient
mice rapidly induced anti-IGF-2 Abs. This response was charac-
terized by a T-independent response (both IgM and IgG3) and after
the second injection, a T-dependent response with IgG1, IgG2a,
and IgG2b production. Contrary to Igf2/ mice, wt mice pre-
sented only IgM and IgG3 production with a similar titer, but no
T-dependent response was observed.
FIGURE 5. Production of IGF-2-
specific Abs and T cells by wt and
Igf2/ mice after i.p. immunization.
A, Analysis of different isotypes: IgM
and IgG3 present the T-independent
responses and IgG1, IgG2a, and
IgG2b the T-dependent responses. Se-
rial dilutions were performed, and
data represent the percentage of the
OD in preimmune serum at the dilu-
tion 1/200 for IgM and IgG3, 1/500
for IgG2a and IgG2b, and 1/10,000
for IgG1. These histograms represent
four representative wt mice and four
representative Igf2/ mice (n  8 of
each kind of mice). B, IL-2 produc-
tion by IGF-2-specific T cells from wt
and Igf2/ mice after two i.p. injec-
tions of IGF-2-derived B11-25 and
one in vitro stimulation; *, p  0.05
(n  8 of each kind of mice).
FIGURE 6. Insulin-specific humoral response in wt and Igf2/ mice
after i.p. immunization. The analysis of Ig production following injection
was performed in mice with Ig production at day 0 lower than 1 in OD.
Serial dilutions were performed, and data represent the percentage of the
OD in preimmune serum at the dilution 1/100. Mean  SEM; *, p  0.05
(n  6/8 of each kind of mice).
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The proliferation of IGF-2-derived B11-25-specific T cells ac-
tivated after immunization was characterized by IL-2 production
with or without in vitro stimulation by IGF-2-derived B11-25 (Fig.
5B). In culture with murine IGF-2-derived B11-25, spleen cells
from Igf2/ mice present a significant increase of IL-2 produc-
tion when compared with wt mice. This IL-2 production was spe-
cific of B11-25 because cultures without B11-25 did not show any
IL-2 secretion.
Characterization of anti-insulin specific humoral response
Igf2/ and wt mice were immunized with insulin to evaluate
anti-insulin-specific humoral response. We observed that Ig re-
sponse following immunization was dependent of anti-insulin Ig
level in preimmune serum. Mice with high insulin-specific Ig pro-
duction before immunization did not display any response to in-
jections (data not shown). We decided to consider mice with anti-
insulin Ab level at day 0 lower than 1 in OD. Igf2/ mice
presented a higher anti-insulin Ig-specific humoral response fol-
lowing the three injections compared with Igf2/ mice (Fig. 6).
Discussion
The main objective of this study was to evaluate the importance of
IGF-2 in immune development and physiology. The absence of
Igf2 expression does not influence lymphoid organ development as
shown by a similar growth of thymus and spleen, as well as a
cellularity in both organs and BM, which is identical in wt and
Igf2/ mice. In Igf2-deficient mice, thymocyte development is
not affected but, in the spleen, a significant increase of
CD4CD8 cells and a lower B220 population is observed.
We decided in a second step to investigate the effect of Igf2
deficiency on the maturation and function of DC, the most potent
APC (22) implicated in polarization of the immune response, i.e.,
immunity vs tolerance (23, 24). It has been previously reported
that IGF-1 promotes maturation and inhibits apoptosis of immature
cord blood monocyte-derived DC (25). The switch from iDC to
mDC stage reduces the IGF-1 mRNA level as shown by DNA
array (26). In normal mice, BM-derived DC express IGF and
IGF-R genes at all differentiation stages (BM cells, iDC, and
mDC), but our RT-PCR conditions failed to detect any Ins1
and Ins2 transcripts in all DC subtypes. All genes detected in wt
samples were found in Igf2/ BM cells, Igf2/ iDC, and
Igf2/ mDC except Igf2 for which the expression was severely
decreased. Sequencing of PCR products confirmed the specificity
of these Igf2/ transcripts. With a high number of PCR cycles,
some products can be detected from the turnover of read-through
primary transcript. However, these transcripts cannot generate a
functional protein because the deleted exon 4 encodes the signal
peptide and 28 residues of mature IGF-2 (4, 27). After having
checked that DC express the genes of different factors implicated
in a potential action of insulin-related factors, we analyzed the
implication of Igf2 deficiency in DC development and acquirement
of molecules implicated in T-DC interactions. In wt mice, BM-
derived DC express CD11c and the majority of these cells are
CD11cLy6GCD8 myeloid DC as described by other groups
with this method using GM-CSF only for DC differentiation (16,
28–30). However, a CD11cLy6GCD8 population was also
identified in our culture conditions. This population could be due
to the source of GM-CSF generated by COS-7 transfection be-
cause the conditioned medium is used in BM cell culture. Other
cytokines present in this medium could also influence DC differ-
entiation. This second DC subset in culture exhibits the character-
istics of plasmacytoid DC (pDC) expressing CD11c and Ly6C/
Ly6G (clone RB6-8C5 recognized Ly6G/Gr1 and Ly6C Ag) (31,
32), and this population is higher in deficient mice compared with
wt mice. In Igf2/ mice, we also observed a significantly higher
iDC population, which persisted 24 to 48 h after LPS maturation
suggesting that this effect was not due to a delay of maturation but
to its absence. The increased immature population as well imma-
ture myeloid DC as pDC in Igf2/ mice is considered to be
tolerogenic DC (33, 34), which are not effective in T cell activa-
tion. Our results concur with this functional status because we
observed a decreased allogenic T cell proliferation in Igf2/
MLR. The implication of IGF-2 is only observed in DC maturation
(no significant difference is observed after 10 days of differentia-
tion); this factor is not implicated in DC development to obtain cell
population with DC characteristics because the percentage of
CD11c population after culture is identical between the two
kinds of mice. The role of IGF-2 in maturation is further confirmed
by semiquantitative PCR showing a higher Igf2 transcription in wt
mDC than in wt iDC. The mechanisms by which IGF-2 intervenes
in maturation is not determined, but in our culture conditions, BM-
derived DC differentiated and maturated in medium supplemented
with 10% FCS (which contains a significant amount of IGF-2).
Igf2/ DC could easily use external IGF-2 to promote their mat-
uration if only the absence of IGF-2 production was implicated.
Igf2 expression deficiency seems to be responsible for the defect
observed in DC maturation, and a deficiency in an IGF-2-mediated
intracrine signaling could be speculated in our experimental
model.
With regard to the role of IGF-2 in T cell development, a thymic
hyperplasia was observed in Igf2 overexpression transgenic mice,
with an increased number of thymocytes and CD4 cells (11, 12).
In our experiments, we observed a significant defect of prolifera-
tion as shown by a decrease in [3H]thymidine uptake, but an early
event in T cell activation such as IL-2 production was not affected.
A recent study based on the inhibitory implication of NK cells on
T cell proliferation suggests that this effect could be due to a direct
impact on p21 and on the cellular cycle without affecting an early
event in T cell activation including IL-2 secretion and IL-2R up-
regulation (35). IGF-2 could also influence the apoptotic phenom-
enon to promote T cell survival in the same way as IGF-1, which
influences T cell survival via Akt and JNK pathway (36). The role
played by IGF-2 could be mediated through IGF-1R, which binds
both IGF-1 and IGF-2, and is regulated during T-lymphocyte ac-
tivation (37). These different ways are under current investigation.
Central self-tolerance of the immune system is established in the
thymus through the MHC presentation of self-antigens transcribed
by thymic stromal cells to immature T cells and through the gen-
eration of self-antigen-specific regulatory T cells (for review, see
Refs. 38 and 39). With regard to the insulin gene family, all mem-
bers of this family are transcribed in the murine thymus according
to a precise hierarchy and topography of their expression profile:
Igf2 (cortical (c) and medullary (m) thymic epithelial cells
(TEC))  Igf1 (macrophages)  Ins2 (mTEC)  Ins1 (mTEC)
(9, 40). A thymus-specific defect of Igf2 transcription has been
observed in BB rats, an animal model of type 1 diabetes, strongly
suggesting some impaired tolerance to IGF-2 in this disease (15).
As expected, Igf2/ mice are completely intolerant of IGF-2 as
confirmed by our immunization experiments. Indeed, only Igf2-
deficient mice immunized with IGF-2 develop IgG1, IgG2a, and
IgG2b following an isotypic switch that requires the help of IGF-
2-specific CD4 T cells. These T cells were detected by IL-2 pro-
duction in culture stimulated by IGF-2-derived B11-25. In wt mice
immunized with IGF-2, these switch and cellular responses were
not observed confirming a complete tolerance to IGF-2. In the
same mouse model, influence of IGF-2 upon tolerance to insulin
was also assessed. This study showed that Igf2/ mice present a
lower tolerance to insulin than Igf2/ mice. The insulin-specific
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Ab level in preimmune serum is correlated with the immune re-
sponse suggesting the capture of insulin by these specific Abs. This
phenomenon would influence the Ag availability for immune re-
sponse. We can conclude that IGF-2 is able to mediate its own
tolerance and also contributes to insulin tolerance. Insulin is the
only -cell-specific autoantigen in this disease and was recently
demonstrated to be the primary target recognized by the immune
system and initiator of the autoimmune response (41, 42). Theo-
retically, immunization of Igf2/ mice with IGF-2 should allow
cloning of IGF-2-specific CD4 lymphocytes and to investigate
the pathogenic properties of these “forbidden” self-reactive clones.
This will further provide significant help in understanding the con-
sequences of a thymic Igf2 defect in the establishment of immune
self-tolerance to the whole insulin family and in type 1 diabetes
pathogenesis.
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